MERTK and head and neck squamous cell carcinoma: Due to the success of the dual Axl and MerTK inhibitor, INCB081776, in preclinical HNSCC models, the SPORE resubmission included a pilot study evaluating the safety and efficacy of INCB081776 in combination with anti-PD1 checkpoint blockade (pembrolizumab) and palliative radiation in HNSCC patients.